In this episode of the "The Top Line," we talk with Fierce’s Gabrielle Masson and Andrea Park about the most important news coming from this year's annual ASCO meeting. We also cover contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. 

To learn more about the topics in this episode:
ASCO: Novocure's tumor-treating electric fields nearly double survival for some lung cancer patients
ASCO: Astellas exec jokes that 3 pending drug approvals are turning his hair gray
ASCO: J&J's multiple myeloma combo produces déjà vu with 96% Carvykti-like response
ASCO: Illumina's oncology exec on the need to 'democratize genomic profiling in cancer'
Merck challenges HHS on Medicare drug price negotiations, alleging violations of the Constitution
Akili launches over-the-counter version of attention-improving video game for adults with ADHD
FDA document outlines apparent agency support for full approval of Biogen, Eisai's Leqembi

"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

In this episode of the "The Top Line," we talk with Fierce’s Gabrielle Masson and Andrea Park about the most important news coming from this year's annual ASCO meeting. We also cover contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. 
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercebiotech.com/medtech/asco-novocures-tumor-treating-electric-fields-nearly-double-survival-some-lung-cancer" data-cke-saved-href="https://www.fiercebiotech.com/medtech/asco-novocures-tumor-treating-electric-fields-nearly-double-survival-some-lung-cancer">ASCO: Novocure's tumor-treating electric fields nearly double survival for some lung cancer patients </a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-astellas-takes-conferences-theme-heart-takes-aim-3-oncology-approvals-12-months" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-astellas-takes-conferences-theme-heart-takes-aim-3-oncology-approvals-12-months">ASCO: Astellas exec jokes that 3 pending drug approvals are turning his hair gray</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response" data-cke-saved-href="https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response">ASCO: J&amp;J's multiple myeloma combo produces déjà vu with 96% Carvykti-like response</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/asco-illumina-oncology-exec-need-democratize-genomic-profiling-cancer" data-cke-saved-href="https://www.fiercebiotech.com/medtech/asco-illumina-oncology-exec-need-democratize-genomic-profiling-cancer">ASCO: Illumina's oncology exec on the need to 'democratize genomic profiling in cancer'</a></li>
<li><a href="https://www.fiercepharma.com/pharma/merck-challenges-hhs-medicare-drug-price-negotiations-lawsuit-alleging-constitutional" data-cke-saved-href="https://www.fiercepharma.com/pharma/merck-challenges-hhs-medicare-drug-price-negotiations-lawsuit-alleging-constitutional">Merck challenges HHS on Medicare drug price negotiations, alleging violations of the Constitution</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/akili-launches-over-counter-version-attention-improving-video-game-adults-adhd" data-cke-saved-href="https://www.fiercebiotech.com/medtech/akili-launches-over-counter-version-attention-improving-video-game-adults-adhd">Akili launches over-the-counter version of attention-improving video game for adults with ADHD</a></li>
<li><a href="https://www.fiercepharma.com/pharma/fda-doc-outlines-apparent-agency-support-full-approval-biogen-eisais-leqembi" data-cke-saved-href="https://www.fiercepharma.com/pharma/fda-doc-outlines-apparent-agency-support-full-approval-biogen-eisais-leqembi">FDA document outlines apparent agency support for full approval of Biogen, Eisai's Leqembi</a></li>
</ul>
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement